The China Center for Drug Evaluation, National Medical Products Administration Has Recommended Breakthrough Therapy Designation for ciltacabtagene autoleucel (cilta-cel, LCAR-B38M CAR-T Cells), an Investigational BCMA CAR-T Cell Therapy
First investigational product being recommended for Breakthrough Therapy Designation in China SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech…